Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors — SABR-COMET 10

Metastatic Tumors Clinical Trial

Official title:
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10)

Status Active, not recruiting

Clinical Trial Summary

In patients with a limited oligometastatic burden (cancer has spread but is not yet considered metastatic), emerging evidence suggests that treatment of all sites of disease with ablative therapies can improve patient outcomes, including overall- and progression-free survival. The application of Stereotactic Ablative Radiotherapy (SABR) for patients with 4-10 metastatic deposits appears promising, yet it is unclear if all patients with greater than 3 oligometastatic lesions benefit from ablative therapies in terms of improved Overall Survival (OS), Progression Free Survival (PFS), or quality of life. The purpose of this study is to assess the impact of SABR, compared to standard of care treatment, on overall survival, oncologic outcomes, and quality of life in patients with a controlled primary tumor and 4-10 metastatic lesions.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03721341
Study type	Interventional
Source	Lawson Health Research Institute
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	February 22, 2019
Completion date	January 2029

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02933242` - Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases	N/A
Active, not recruiting	`NCT01446744` - Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET)	Phase 2
Completed	`NCT00676949` - Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors	Phase 1
Recruiting	`NCT03862911` - Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic (1-3 Metastases) Cancer	N/A
Recruiting	`NCT05390528` - A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma	Phase 1/Phase 2
Completed	`NCT00705497` - Radiofrequency Ablation of Tumors	Phase 1
Completed	`NCT01910545` - Phase 1 Study of OTS167 in Patients With Solid Tumors	Phase 1
Completed	`NCT02156388` - Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors	Phase 1